Patient Questions on the COVID-19 Vaccine: Nurses Weigh In
We spoke with a group of oncology nurses about the questions that patients are asking regarding the COVID-19 vaccine.
We spoke with a group of oncology nurses about the questions that patients are asking regarding the COVID-19 vaccine.
The benefits noted in this exploratory analysis were irrespective of the number of neoadjuvant treatment cycles completed in patients with resectable non-small cell lung cancer.
Oncology nurses can assist in educating patients with sarcoma about clinical trial outcomes and the benefits of participating in trials.
Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.
Patients with EGFR exon 20 insertion–mutated NSCLC treated with amivantamab plus chemotherapy experienced an extension in the time to treatment discontinuation and subsequent therapy.
Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.
Patients with advanced hepatocellular carcinoma treated with nivolumab plus ipilimumab had an improvement in overall survival compared with standard-of-care TKIs.
Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.
Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.
Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.
Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.